The scale scores range from 0 100 with higher scores indicating greater parent impact.
This study introduced the Parent Impact Scale, a four-item scale of the CHRIs General parent-proxy version.
Atomoxetine-treated patients improved on all seven psychosocial outcomes (self-esteem, behavior, family activity, mental health, parent impact emotion, parent impact time, and role function), while no aggravations, or differences versus placebo were seen on the physical functioning domains.
These analyses were performed using total ECOHIS score as a whole and child and parent impact sections separately.
The promising psychometric properties of the PARimpact scale indicate that parent impact is a unidimensional construct with clinical relevance.
We hypothesized that parent impact would be strongly correlated to parents' emotional functioning, moderately correlated with Global QOL, and weakly correlated with parents' general health.
A more complete understanding of the durability of parent vulnerability after BMT could lead to the development of interventions to decrease parent impact during and after BMT.
In this paper we introduce the Parent Impact Scale (PARimpact), designed to capture physical and emotional challenges of the child's health on the parent.
Finally, it is possible that there are other variables that contribute to parent impact during a child's BMT that were not included in the PARimpact scale.
These analyses were performed with data from the community-based sample, using total ECOHIS score as a whole and child and parent impact sections separately.
Health is assessed over several domains including: general health perceptions, physical functioning, role/social physical functioning, bodily pain, role/social emotional and behavioral functioning, parent impact-time and parent impact-emotional, self-esteem, mental health, behavior, family activities and family cohesion.
